Literature DB >> 25288030

The national incidence and clinical picture of SLE in children in Australia - a report from the Australian Paediatric Surveillance Unit.

F E Mackie1, G Kainer2, N Adib3, C Boros4, E J Elliott5, R Fahy6, J Munro7, K Murray8, A Rosenberg2, B Wainstein9, J B Ziegler9, D Singh-Grewal10.   

Abstract

OBJECTIVES: The objectives of this paper are to prospectively determine the incidence of paediatric systemic lupus erythematosus (pSLE) in Australia as well as describe the demographics, clinical presentation and one-year outcome. STUDY
DESIGN: Newly diagnosed cases of pSLE were ascertained prospectively from October 2009 to October 2011 through the Australian Paediatric Surveillance Unit (a national monthly surveillance scheme for notification of childhood rare diseases) as well as national subspecialty groups. Questionnaires were sent to notifying physicians at presentation and at one year.
RESULTS: The annual incidence rate was 0.32 per 10(5) children aged less than 16 years. The incidence was significantly higher in children of Asian or Australian Aboriginal and Torres Strait Islander parents. Approximately one-third of children underwent a renal biopsy at presentation and 7% required dialysis initially although only one child had end-stage kidney disease (ESKD) at one-year follow-up.
CONCLUSION: The incidence of pSLE in Australia is comparable to that worldwide with a significantly higher incidence seen in children of Asian and Australian Aboriginal and Torres Strait Islander backgrounds. Renal involvement is common but progression to ESKD, at least in the short term, is rare.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Australian Aboriginal and Torres Strait Islanders; Systemic lupus erythematosus; incidence; lupus nephritis

Mesh:

Substances:

Year:  2014        PMID: 25288030     DOI: 10.1177/0961203314552118

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  7 in total

1.  Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.

Authors:  Julien Hogan; Astrid Godron; Véronique Baudouin; Theresa Kwon; Jérôme Harambat; Georges Deschênes; Olivier Niel
Journal:  Pediatr Nephrol       Date:  2017-08-05       Impact factor: 3.714

2.  Long-term renal outcomes of childhood-onset global and segmental diffuse proliferative lupus nephritis.

Authors:  Pornpimol Rianthavorn; Athitaya Buddhasri
Journal:  Pediatr Nephrol       Date:  2015-06-09       Impact factor: 3.714

3.  Glucocorticoid discontinuation in pediatric-onset systemic lupus erythematosus: a single-center experience.

Authors:  Kentaro Nishi; Masao Ogura; Sho Ishiwa; Toru Kanamori; Mika Okutsu; Shunsuke Yokota; Taishi Nada; Mai Sato; Koichi Kamei; Kenji Ishikura; Shuichi Ito
Journal:  Pediatr Nephrol       Date:  2022-01-26       Impact factor: 3.651

4.  Increased risk of cervical dysplasia in females with autoimmune conditions-Results from an Australia database linkage study.

Authors:  Emma Foster; Michael J Malloy; Vilija G Jokubaitis; C David H Wrede; Helmut Butzkueven; Joe Sasadeusz; Sharon Van Doornum; Finlay Macrae; Gary Unglik; Julia M L Brotherton; Anneke van der Walt
Journal:  PLoS One       Date:  2020-06-18       Impact factor: 3.240

Review 5.  Kidney outcomes for children with lupus nephritis.

Authors:  Louise Oni; Rachael D Wright; Stephen Marks; Michael W Beresford; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2020-07-28       Impact factor: 3.714

6.  Analysis of Clinicopathological Characteristics and Its Correlation With the Prognosis of Pediatric Lupus Nephritis: A Tertiary Care Center Experience.

Authors:  Barathi G; Mahesh Janarthanan; Indhuumathy Thayammal S; Subalakshmi Balasubramanian; Sangeetha Geminiganesan
Journal:  Cureus       Date:  2022-02-03

7.  Effect of Systemic Lupus Erythematosus on the Risk of Incident Respiratory Failure: A National Cohort Study.

Authors:  Jun-Jun Yeh; Yu-Chiao Wang; Jiunn-Horng Chen; Wu-Huei Hsu
Journal:  PLoS One       Date:  2016-09-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.